Abstract: Compositions comprising clathrin nanoparticles and methods for treating neurological-associated disorders.

Abstract: The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Abstract: The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Abstract: Compositions comprising clathrin nanoparticles and methods for treating dopamine-associated addictions, disorders, and neurodegenerative diseases using the same.

Abstract: The invention in suitable embodiments is directed to dynamic bio-nanoparticle elements and bio-nanoparticle platforms employing such bio-nanoparticle elements. In one aspect, one or more elements of one or more types, formed from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more types of Clathrin and or Coatomer I/II proteins of one or more isoforms, execute one or more functions and or effect one or more ends, in vivo and or in vitro.

Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating neuropsychiatric diseases and disorders.

Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating psychiatric disorders.

Abstract: The invention relates generally to the field of nanoparticles, and more specifically, in one embodiment, to bio-nanoparticle elements formed from materials comprised of self-assembling protein molecules, which are capable of coating one or more type of elements. In another invention embodiment, the invention relates to a protein that coats one or more elements in order to modify or improve one or more characteristic of the element, including, but not limited to, stability, rigidity, or functionality of the element that is coated with the instant invention.

Abstract: The invention in suitable embodiments is directed to a method for cell energy therapeutics, the method comprising inducing an in vivo or in vitro cell to comprise an element for treating a disease, condition, or disorder. In one aspect, a composition comprising a source of energy and an isolated protein is for use in transforming a living cell into a therapeutic, a diagnostic, a sensor, a regenerative, or a cosmetic element for use in treating one or more type of disease, condition, or disorder.

Abstract: The invention in suitable embodiments is directed to using a purified, clathrin light chain protein for purposes of drug development, enablement, activity, and/or delivery. In one aspect, a man-made, configurable clathrin light chain composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more of a protein sequence, forms one or more type of multifunction nanoscale bio-nanoparticle, such as a biomedical platform, bio-molecular platform, and the like, and using such bio-nanoparticle platforms for development, enablement, and delivery of drugs.

Abstract: The invention in suitable embodiments is directed to replacement therapeutics. In one aspect, a medicament is comprised in whole or in part of one or more clathrin heavy chain protein that is formed from a plurality of isolated, synthetic or recombinant clathrin protein molecules. In one embodiment, a man-made clathrin heavy chain protein composition replaces and/or modifies cell elements or processes, in vivo or in vitro, thereby treating a disease, condition, or disorder comprising at least one of cell.

Abstract: The invention in suitable embodiments is directed to using purified, non-cage clathrin protein for purposes of assisting in drug discovery and development. In one aspect, a tool composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more protein sequence, forms one or more type of tool for carrying out various elements and activities of drug discovery and development.

Abstract: The invention in suitable embodiments is directed to purified non-cage clathrin protein compositions. In one aspect, one or more purified non-cage clathrin protein composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues, forms a composition to repurpose at least one aspect of a medicament or use thereof when the medicament is formulated with the non-cage clathrin protein.

Abstract: The invention in suitable embodiments is directed to plasmon energy therapeutics. In one embodiment the instant invention is a medicament composition in which manmade nanoscale elements, such as ultrabright fluorescent molecules and emitting photons of a luminance equivalent to at least a luminance of photons emitted by a quantum dot, are disposed adjacent to dielectric elements and further including multiple metal molecules capable of photo-accepting the emitted photons. In one aspect, the composition produces chemical, electrical, electromagnetic, optical, plasmonic, or thermal energy. In one embodiment, the invention is a drug for use in treating a disease, condition, or disorder. In another embodiment, energy is produced, captured or stored or directed or transduced by the composition for use by a cell.

Abstract: The invention in suitable embodiments is directed to cell energy therapeutics enabled by ultrabright fluorescent molecules and emitting photons of a luminance equivalent to at least a luminance of photons emitted by a quantum dot and bound to a dielectric protein capable of non-invasively entering a living cell. In one aspect, a composition is for use in transforming a living cell into an energy medicine therapeutic capable of supplying one or more type of electrical or electromagnetic or optical or thermal therapeutic energy for use in treating one or more type of disease, condition, or disorder.

Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating various types of a cancerous disease, condition, or disorder in vivo or in vitro.

Abstract: The invention in suitable embodiments is directed to energy medicine therapeutic compositions enabled by man-made clathrin proteins. In one aspect, one or more purified clathrin protein, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, and including one or more of an element or a material for use in supplying an electrical, an electromagnetic, a photonic, a quantum, or a thermal action or effect to a biological element or a biological process, form one or more type of therapeutic composition for treating a cell process, a genotype or a phenotype disease, condition, or disorder, in vivo or in vitro.

Abstract: The invention in suitable embodiments is directed to self-adapting, scalable, and communicating sensor platforms that are further capable of autonomous and/or cognitive action. In one aspect, the invention relates to a multifunction sensor platform, such as a biomedical sensor platform, bio-molecular sensor platform, electronics sensor platform, communications sensor platform, information processing sensor platform, and the like. In another invention embodiment, one or more sensors improve the efficacy of a healthcare element and/or its usage in treating and/or preventing a disease, condition, or disorder.

Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an autoimmune disease, condition, or disorder in vivo or in vitro.

Abstract: The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating a neurological disease, condition, or disorder in vivo or in vitro.